Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

The New England journal of medicine - 30 Apr 2015

Jänne Pasi A, Yang James Chih-Hsin, Kim Dong-Wan, Planchard David, Ohe Yuichiro, Ramalingam Suresh S, Ahn Myung-Ju, Kim Sang-We, Su Wu-Chou, Horn Leora, Haggstrom Daniel, Felip Enriqueta, Kim Joo-Hang, Frewer Paul, Cantarini Mireille, Brown Kathryn H, Dickinson Paul A, Ghiorghiu Serban, Ranson Malcolm

Abstract excerpt

BACKGROUND: The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 25923549
DOI: 10.1056/NEJMoa1411817

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.PMID 25923549Read ↗

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Semantic proximity Read ↗

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.Semantic proximity Read ↗

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.Semantic proximity Read ↗

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.Semantic proximity Read ↗

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.Semantic proximity Read ↗

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Semantic proximity Read ↗

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Semantic proximity Read ↗

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Semantic proximity Read ↗

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.Semantic proximity Read ↗

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)Semantic proximity Read ↗

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.